枸橼酸莫沙必利治疗帕金森综合征患者消化道功能紊乱的疗效

发布时间：2019-08-03 06:12

【摘要】：目的:探讨枸橼酸莫沙必利对帕金森综合征患者下消化道功能紊乱的治疗作用,阐明其作用机制。方法:选择伴有消化道功能紊乱的帕金森综合征患者29例,其中男性19例,女性10例,平均年龄68.7岁,每日给予枸橼酸莫沙必利15mg,分3次口服,连续3个月。测定患者结肠通过时间(CTT),行结直肠造影测定患者不同阶段直肠内压力和容量。结果:经枸橼酸莫沙必利治疗后,所有患者排便困难均好转。与治疗前比较,枸橼酸莫沙必利治疗后患者平均CTT缩短(P0.05),尤其是左半部CTT缩短明显(P0.01);与治疗前比较,枸橼酸莫沙必利治疗后,在直肠充盈的过程中,初发便意明显降低(P0.05)。结论:枸橼酸莫沙必利作为一种新型5-HT4受体兴奋剂及5-HT3受体拮抗剂,对帕金森综合征患者具有促进结直肠蠕动及通便的作用。
[Abstract]:Objective: to investigate the therapeutic effect of mosapride citrate on lower gastrointestinal dysfunction in patients with Parkinson's syndrome (PD) and to elucidate its mechanism. Methods: 29 patients with Parkinson's syndrome with digestive tract dysfunction, including 19 males and 10 females, with an average age of 68.7 years, were treated with mosapride citrate 15 mg per day for 3 months. The colon transit time (CTT), was measured by colorectal angiography to measure the rectal pressure and volume at different stages. Results: after mosapride citrate treatment, all patients with defecation difficulty improved. Compared with before treatment, the average CTT of patients treated with mosapride citrate was shortened (P 0.05), especially the left half CTT was shortened significantly (P 0.01). Compared with before treatment, the initial stool intention decreased significantly in the process of rectal filling after mosapride citrate treatment (P 0.05). Conclusion: mosapride citrate, as a new 5-HT4 receptor stimulant and 5-HT3 receptor antagonist, can promote colorectal peristalsis and defecation in patients with Parkinson's syndrome.
【作者单位】：北华大学基础医学院病理生理学教研室;吉林省吉林市中心医院神经科;北华大学附属医院神经二科;
【基金】：吉林省教育厅科研基金资助课题(2015-164;2013-162;2013-315)
【分类号】：R742.5;R57

【相似文献】